Core Viewpoint - Yiming Pharmaceutical (002826) is undergoing a board restructuring following the completion of its third board term, marking the first adjustment since the entry of 58.com founder Yao Jinbo into the company [1][4] Group 1: Board Restructuring - The new fourth board will consist of 7 directors, down from 8, including 3 independent directors, 3 non-independent directors, and 1 employee director [2] - All independent and non-independent directors from the previous board will be replaced [2] - Candidates for non-independent directors include Fu Lihua, Huang Lingyi, and Yao Yan, with backgrounds in management and education technology [2][3] Group 2: Shareholding Changes - Beijing Fuhao is expected to secure all non-independent director positions, indicating a new era under Yao Jinbo's leadership [4] - In May, Beijing Fuhao signed a share transfer agreement to acquire 23% of Yiming Pharmaceutical's shares from the former controlling shareholder, Gao Fan, at a price of 15.10 yuan per share, totaling 662 million yuan [4] Group 3: Company Overview - Yiming Pharmaceutical primarily engages in drug sales and promotion services, with a focus on cardiovascular and diabetes-related products [4] - The company's core product, Miglitol tablets, holds a leading market share in the domestic Miglitol market for type 2 diabetes treatment [4] - The company has maintained stable annual revenues of approximately 650 million yuan over the past two years [4] Group 4: Market Implications - Yao Jinbo's entry into the pharmaceutical industry has generated significant market interest regarding the potential resources and advantages he may bring to the company [5] - Beijing Fuhao has expressed intentions to leverage its strengths in investment management and industry planning to empower the company's business development [5]